Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechnology: Archive
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
by Zacks Equity Research
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change CADLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Helios Technologies (HLIO) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HLIONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
by Zacks Equity Research
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
APLSNegative Net Change ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
by Zacks Equity Research
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
NVSNegative Net Change KRYSNegative Net Change MORNegative Net Change ALXONegative Net Change
biotechnology biotechs pharmaceuticals
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
by Zacks Equity Research
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
VSTMNegative Net Change ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
by Zacks Equity Research
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
ENTXNegative Net Change BCYCNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy New York Times Co. (NYT) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
NYTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
by Zacks Equity Research
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
GSKNegative Net Change BIIBNegative Net Change PTCTNegative Net Change IONSPositive Net Change LRMRPositive Net Change
biotechnology
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
REGNNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
DCPHPositive Net Change ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
KRYSNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
KE Holdings Inc. Sponsored ADR (BEKE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BEKEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SAVANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
BMYNegative Net Change LGNDNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
RDYPositive Net Change ANVSNegative Net Change ALXONegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
First Interstate BancSystem (FIBK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FIBKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
by Zacks Equity Research
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
DYNNegative Net Change LGNDNegative Net Change SRPTNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
LGNDNegative Net Change PTCTNegative Net Change ANIPPositive Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
by Zacks Equity Research
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
TEVAPositive Net Change EXELNegative Net Change LGNDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Sierra Bancorp (BSRR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BSRRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
by Zacks Equity Research
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
LGNDNegative Net Change ANIPPositive Net Change BGNENegative Net Change ANVSNegative Net Change
biotechnology biotechs medical oncology-screening precious-metals
Gilead (GILD) Announces Positive Interim Results on PBC Drug
by Zacks Equity Research
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
GILDNegative Net Change LGNDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy CareCloud, Inc. (CCLD) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CCLDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
iPower Inc. (IPW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
IPWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exponent (EXPO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EXPONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines